• No results found

Formulation and Evaluation of Teneligliptin and Telmisartan Bilayer Tablets for the Treatment of Coexistent Type II Diabetes Mellitus and Hypertension

N/A
N/A
Protected

Academic year: 2020

Share "Formulation and Evaluation of Teneligliptin and Telmisartan Bilayer Tablets for the Treatment of Coexistent Type II Diabetes Mellitus and Hypertension"

Copied!
13
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

Table No.1: Compositions of Sustained Release Layer of Teneligliptin :-
Table No.2 : Compositions of Sustained Release Layer of Telmisartan :-
Table No.5 : Procedure for Dissolution Study
Table no. 6 Biological activity profile table (A1, B1, C1 are doses of Teneligliptin and A2, B2, C2 are doses of Telmisartan respectively
+7

References

Related documents

Seventy-two patients with mixed hemorrhoids who had undergone hemorrhoidectomy were randomly assigned to the following 2 groups: the EA treatment group (EA) received surround

Anterior tibial translation (mean ± SD) in the intact, anterior cruciate ligament (ACL)-deficient, and anatomic double bun- dle and single posterolateral (PL) bundle ACL-reconstructed

In this systematic review, 4 studies of femoral or acetab- ular defects, 3 studies of tibial fractures, 2 studies of large bone defects, 2 bone tumors studies, 2 studies of

The factors that are considered include the time to initiate chest com- pressions, duration of chest compressions, initial arrest rhythm, age, comorbidities and any reversible causes

We also compared the AUC of machine learning using the network topology to the logis- tic regression based on the standard financial measures (non-network information): firm

The most important problem in our case was the emergency treatment of bleeding esophageal varices in a patient with portal hypertension secondary to portal vein thrombosis..

An English translation (accuracy confirmed by back translation) of the two ques- tionnaires on personal preference is shown in Table 1. Similar statements with appropriate

of coverage established in our exome sequencing, we did not identify any two patients who had de novo variants in the same gene, any de novo coding variants unique to the tumours,